Get the Stockscreener App
0.855
0.04%
0.005
Revelation Biosciences Inc stock is traded at $0.855, with a volume of 31,697.
It is up +0.04% in the last 24 hours and down -31.98% over the past month.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
See More
Previous Close:
$0.85
Open:
$0.8466
24h Volume:
31,697
Relative Volume:
0.08
Market Cap:
$5.04M
Revenue:
-
Net Income/Loss:
$-15.52M
P/E Ratio:
-0.046
EPS:
-18.58
Net Cash Flow:
$-16.61M
1W Performance:
-5.44%
1M Performance:
-31.98%
6M Performance:
-66.85%
1Y Performance:
-92.94%
1-Day Range:
$0.831
$0.8799
1-Week Range:
$0.8301
$0.95
52-Week Range:
$0.702
$20.16
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650-800-3717
Address
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
0.8503 | 5.04M | 0 | -15.52M | -16.61M | -18.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.49 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.63 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
439.97 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
923.67 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.06 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Revelation Biosciences Inc Stock (REVB) Latest News
Can Revelation Biosciences Inc. Equity Warrant stock sustain free cash flow growthLong Setup & Accurate Entry/Exit Alerts - newser.com
How Revelation Biosciences Inc. stock reacts to global recession fearsJuly 2025 News Drivers & High Accuracy Investment Signals - newser.com
Revelation Says On Track for FDA Meeting Later This Year - MarketScreener
Revelation Biosciences on track for end-of-phase 1 meeting later this year - TipRanks
Revelation Biosciences submits end-of-phase 1 package to FDA - Investing.com
Revelation Biosciences submits end-of-phase 1 package to FDA By Investing.com - Investing.com South Africa
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year - Weatherford Democrat
Revelation Biosciences (NASDAQ: REVB) Advances Gemini AKI Program With FDA Phase 1 Meeting - Stock Titan
Chart based analysis of Revelation Biosciences Inc. Equity Warrant trends2025 Valuation Update & Precise Buy Zone Identification - newser.com
How Revelation Biosciences Inc. Equity Warrant stock performs in weak economyGold Moves & Short-Term Trading Alerts - newser.com
How Revelation Biosciences Inc. Equity Warrant stock reacts to oil pricesWall Street Watch & Fast Gaining Stock Strategy Reports - newser.com
How institutional buying supports Revelation Biosciences Inc. Equity Warrant stockWeekly Trend Report & Intraday High Probability Setup Alerts - newser.com
Using RSI to spot recovery in Revelation Biosciences Inc. Equity Warrant2025 Market Trends & Expert Curated Trade Ideas - newser.com
Using Bollinger Bands to evaluate Revelation Biosciences Inc. Equity Warrant2025 Volume Leaders & High Conviction Investment Ideas - newser.com
Analyzing recovery setups for Revelation Biosciences Inc. Equity Warrant investorsMarket Movement Recap & Accurate Entry and Exit Point Alerts - newser.com
What catalysts could drive Revelation Biosciences Inc. Equity Warrant stock higher2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
Can Revelation Biosciences Inc. stock continue upward trendPortfolio Profit Report & Long Hold Capital Preservation Tips - newser.com
Best data tools to analyze Revelation Biosciences Inc. Equity Warrant stockWeekly Loss Report & Weekly Breakout Stock Alerts - newser.com
Why Revelation Biosciences Inc. stock could outperform in 2025 - newser.com
Published on: 2025-11-16 12:31:36 - newser.com
Revelation Biosciences Inc. stock retracement – recovery analysisIPO Watch & Real-Time Chart Pattern Alerts - newser.com
Analyzing Revelation Biosciences Inc. with multi timeframe charts2025 Trading Volume Trends & Reliable Price Action Trade Plans - newser.com
Volume spikes in Revelation Biosciences Inc. stock – what they mean2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025 - El Paso Times
Will Revelation Biosciences Inc. Equity Warrant stock outperform Dow Jones indexWeekly Profit Report & Fast Gain Stock Tips - newser.com
Using data filters to optimize entry into Revelation Biosciences Inc.Rate Cut & Risk Adjusted Buy/Sell Alerts - newser.com
Revelation Biosciences Inc Stock (REVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):